Years Active: 2025
Title: Yanfeng Zhou: Innovator in Immunotherapy
Introduction
Yanfeng Zhou is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of immunotherapy, particularly in the development of multifunctional binding proteins. His work focuses on enhancing the efficacy of treatments for proliferative disorders, including multiple myeloma.
Latest Patents
Yanfeng Zhou holds a patent for "Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with Fc-engineering." This patent describes multifunctional binding proteins that consist of a first and a second antigen binding domain (ABD) along with an immunoglobulin Fc region or its variant. The first ABD specifically binds to human BCMA, while the second ABD binds to human NKp46. Additionally, the Fc region is designed to bind to a human Fc-γ receptor. This innovation has potential applications in the treatment and prevention of proliferative disorders, including multiple myeloma.
Career Highlights
Throughout his career, Yanfeng Zhou has demonstrated a commitment to advancing medical science through innovative research. His work has not only contributed to the understanding of immune responses but also paved the way for new therapeutic strategies in oncology.
Collaborations
Yanfeng Zhou has collaborated with notable colleagues, including Nicolas Gourdin and Laurent Gauthier. These partnerships have enhanced the scope and impact of his research, leading to advancements in the field of immunotherapy.
Conclusion
Yanfeng Zhou's contributions to the field of immunotherapy exemplify the importance of innovation in medical research. His patent on NK cell engagers represents a significant step forward in the treatment of multiple myeloma and other proliferative disorders.